Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.
Bannoud N, Stupirski JC, Cagnoni AJ, Hockl PF, Pérez Sáez JM, García PA, Mahmoud YD, Gambarte Tudela J, Scheidegger MA, Marshall A, Corrie PG, Middleton MR, Mariño KV, Girotti MR, Croci DO, Rabinovich GA.
Bannoud N, et al.
Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2214350120. doi: 10.1073/pnas.2214350120. Epub 2023 Jan 12.
Proc Natl Acad Sci U S A. 2023.
PMID: 36634146
Free PMC article.
Clinical Trial.